{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T11:41:21Z","timestamp":1768736481581,"version":"3.49.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals USA Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.cca.2024.119843","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T08:32:28Z","timestamp":1719909148000},"page":"119843","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Fabry disease Enzyme Enhancement on migalastat Study: FEES"],"prefix":"10.1016","volume":"561","author":[{"given":"Mathura","family":"Kugan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"D\u2019Amore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udita","family":"Mitra-Royhurst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sneha","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek","family":"Burke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Heales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4703-7447","authenticated-orcid":false,"given":"Uma","family":"Ramaswami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2024.119843_b0005","doi-asserted-by":"crossref","unstructured":"Desnick RJ, Ioannou YA, Eng CM. Alpha-galactosidase A deficiency: Fabry disease in: Scriver CR, et al. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. McGraw-Hill; 2001. p. 3733-74.","DOI":"10.1006\/rwgn.2001.0443"},{"issue":"8","key":"10.1016\/j.cca.2024.119843_b0010","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"10.1016\/j.cca.2024.119843_b0015","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.cca.2024.119843_b0020","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13023-023-02999-6","article-title":"Fabry App: the value of a portable technology in recording day-to-day patient monitored information in patients with Fabry disease","volume":"19","author":"D'Amore","year":"2024","journal-title":"Orphanet. J. Rare Dis."},{"issue":"5","key":"10.1016\/j.cca.2024.119843_b0025","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2016090964","article-title":"Characterization of classical and nonclassical fabry disease: a multicenter study","volume":"28","author":"Arends","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.cca.2024.119843_b0030","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/mgg3.389","article-title":"Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study","volume":"6","author":"Germain","year":"2018","journal-title":"Mol. Genet Genomic Med."},{"issue":"4","key":"10.1016\/j.cca.2024.119843_b0035","doi-asserted-by":"crossref","first-page":"e0193550","DOI":"10.1371\/journal.pone.0193550","article-title":"Phenotype and biochemical heterogeneity in late onset Fabry disease defined by N215S mutation","volume":"13","author":"Lavalle","year":"2018","journal-title":"PLoS One."},{"key":"10.1016\/j.cca.2024.119843_b0040","unstructured":"Gal A, Schafer E, Rohard I. The genetic basis of Fabry disease. 2006."},{"issue":"1","key":"10.1016\/j.cca.2024.119843_b0045","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/4801","article-title":"Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor","volume":"5","author":"Fan","year":"1999","journal-title":"Nat Med."},{"issue":"2","key":"10.1016\/j.cca.2024.119843_b0050","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1042\/BJ20070479","article-title":"Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin","volume":"406","author":"Ishii","year":"2007","journal-title":"Biochem. J."},{"issue":"1","key":"10.1016\/j.cca.2024.119843_b0055","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1096\/fj.04-2375com","article-title":"A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder","volume":"19","author":"Yam","year":"2005","journal-title":"FASEB J."},{"issue":"4","key":"10.1016\/j.cca.2024.119843_b0060","doi-asserted-by":"crossref","first-page":"C1076","DOI":"10.1152\/ajpcell.00426.2005","article-title":"Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants","volume":"290","author":"Yam","year":"2006","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"3","key":"10.1016\/j.cca.2024.119843_b0065","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s10545-009-1077-0","article-title":"The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines","volume":"32","author":"Benjamin","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1","key":"10.1016\/j.cca.2024.119843_b0070","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.cca.2024.119843_b0075","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA."},{"key":"10.1016\/j.cca.2024.119843_b0080","article-title":"Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study","author":"Wallace","year":"2023","journal-title":"J Med Genet."},{"issue":"6","key":"10.1016\/j.cca.2024.119843_b0085","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of fabry's disease with the pharmacologic chaperone migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N Engl J Med."},{"issue":"4","key":"10.1016\/j.cca.2024.119843_b0090","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/gim.2016.122","article-title":"The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat","volume":"19","author":"Benjamin","year":"2017","journal-title":"Genet Med."},{"key":"10.1016\/j.cca.2024.119843_b0095","article-title":"The migalastat GLP-HEK assay is the gold standard for determining amenability in patients with Fabry disease","volume":"20","author":"Schiffmann","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"2","key":"10.1016\/j.cca.2024.119843_b0100","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/cpdd.1","article-title":"Pharmacokinetics and safety of migalastat HCl and effects on agalsidase activity in healthy volunteers","volume":"2","author":"Johnson","year":"2013","journal-title":"Clin. Pharmacol. Drug Dev."},{"issue":"3","key":"10.1016\/j.cca.2024.119843_b0105","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1023\/B:BOLI.0000031101.12838.c6","article-title":"Enzyme replacement and enhancement therapies for lysosomal diseases","volume":"27","author":"Desnick","year":"2004","journal-title":"J. Inherit. Metab. Dis."},{"issue":"4","key":"10.1016\/j.cca.2024.119843_b0110","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J. Med. Genet."},{"issue":"8","key":"10.1016\/j.cca.2024.119843_b0115","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/jmedgenet-2019-106005","article-title":"Mutation-specific Fabry disease patient-derived cell model to evaluate the amenability to chaperone therapy","volume":"56","author":"Lenders","year":"2019","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.cca.2024.119843_b0120","unstructured":"Centogene - The Rare Disease Company: centogene.com. Centogene. 2024. https:\/\/www.centogene.com\/."},{"key":"10.1016\/j.cca.2024.119843_b0125","unstructured":"Human Tissue (Scotland) Act 2006. legislation gov uk. 2024. https:\/\/www.legislation.gov.uk\/asp\/2006\/4\/contents."},{"issue":"6","key":"10.1016\/j.cca.2024.119843_b0130","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1111\/j.1523-1755.2005.00365.x","article-title":"Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"67","author":"Levey","year":"2005","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.cca.2024.119843_b0135","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/ki.2013.444","article-title":"Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward","volume":"85","author":"Levin","year":"2014","journal-title":"Kidney Int."},{"key":"10.1016\/j.cca.2024.119843_b0140","unstructured":"ICH E6 (R2) Good clinical practice - Scientific guideline. European Medical Agency. 2024. https:\/\/www.ema.europa.eu\/en\/ich-e6-r2-good-clinical-practice-scientific-guideline."},{"key":"10.1016\/j.cca.2024.119843_b0145","unstructured":"WMA DECLARATION OF HELSINKI \u2013 ETHICAL PRINCIPLES FOR MEDICAL RESEARCH INVOLVING HUMAN SUBJECTS. World Medical Association. 2024. https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects\/."},{"issue":"1","key":"10.1016\/j.cca.2024.119843_b0150","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12968-017-0327-9","article-title":"Reference ranges for cardiac structure and function using cardiovascular magnetic resonance (CMR) in Caucasians from the UK Biobank population cohort","volume":"19","author":"Petersen","year":"2017","journal-title":"J. Cardiovasc. Magn. Reson."},{"issue":"2","key":"10.1016\/j.cca.2024.119843_b0155","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/jimd.12167","article-title":"Fabry disease genotype, phenotype, and migalastat amenability: Insights from a national cohort","volume":"43","author":"Nowak","year":"2020","journal-title":"J. Inherit. Metab. Dis."},{"issue":"10","key":"10.1016\/j.cca.2024.119843_b0160","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/imj.15473","article-title":"Impact of SARS-CoV-2 (COVID-19) pandemic on patients with lysosomal storage disorders and restoration of services: experience from a specialist centre","volume":"51","author":"Ramaswami","year":"2021","journal-title":"Intern. Med. J."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898124020953?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898124020953?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T11:45:01Z","timestamp":1720957501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898124020953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":32,"alternative-id":["S0009898124020953"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2024.119843","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fabry disease Enzyme Enhancement on migalastat Study: FEES","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2024.119843","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"119843"}}